• DOI:10.1148/RADIOL.2243011553
• Corpus ID: 18417727

Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging.

@article{Beyersdorff2002PatientsWA,
  title={Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging.},
  author={Dirk Beyersdorff and Matthias Taupitz and Bjoern Winkelmann and Thomas Fischer and Severin V. Lenk and Stefan A. Loening and Bernd Hamm},
  journal={Radiology},
  year={2002},
  volume={224 3},
  pages={
          701-6
        }
}

• D. Beyersdorff, M. Taupitz, +4 authors B. Hamm
• Published 1 September 2002
• Medicine
• Radiology

PURPOSE
To determine the role of magnetic resonance (MR) imaging performed with a combined endorectal body phased-array coil for patients with elevated prostate-specific antigen (PSA) levels or suspicious free-to-total PSA ratios in whom prior transrectal ultrasonographically (US) guided biopsy findings were negative for prostate cancer.

MATERIALS AND METHODS
Forty-four patients with PSA levels greater than 4 ng/mL or free-to-total PSA ratios lower than 15% but negative biopsy findings were examined with T1- and T2-weighted MR imaging at 1.5 T with a combined endorectal body phased-array coil. All patients underwent digital rectal examination (DRE) and transrectal US. Thirty-eight patients underwent repeat biopsy after MR imaging. The accuracy of MR imaging for detection of prostate cancer was assessed prospectively. Retrospectively, MR imaging findings were correlated with individual biopsy site findings. MR imaging and biopsy results were correlated by using a cross table to calculate sensitivity, specificity, and positive predictive value (PPV). Retrospective analysis results were evaluated with receiver operating characteristic analysis. A P value of less than.05 indicated significance (chi(2) test according to Pearson).

RESULTS
At prospective analysis, MR imaging had a sensitivity of 83% and a PPV of 50% for detection of prostate cancer; these values were 33% and 67%, respectively, for DRE and 33% and 57%, respectively, for transrectal US. At retrospective site-by-site analysis, MR imaging results did not correlate significantly with individual biopsy site findings (P =.126); sensitivity was 65% and PPV was 12%.

CONCLUSION
In this patient population, MR imaging has higher sensitivity for detection of prostate cancer than DRE or transrectal US.